Symbols / NTRB
NTRB Chart
About
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 52.05M |
| Enterprise Value | 46.92M | Income | -34.59M | Sales | 2.28M |
| Book/sh | 0.62 | Cash/sh | 0.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -18.59 | PEG | — |
| P/S | 22.84 | P/B | 6.88 | P/C | — |
| EV/EBITDA | -5.20 | EV/Sales | 20.59 | Quick Ratio | 7.07 |
| Current Ratio | 7.53 | Debt/Eq | 3.42 | LT Debt/Eq | — |
| EPS (ttm) | -3.05 | EPS next Y | -0.23 | EPS Growth | — |
| Revenue Growth | -46.40% | Earnings | 2025-12-11 06:00 | ROA | -55.22% |
| ROE | -136.08% | ROIC | — | Gross Margin | 33.50% |
| Oper. Margin | -11.21% | Profit Margin | 0.00% | Shs Outstand | 12.17M |
| Shs Float | 4.91M | Short Float | 3.87% | Short Ratio | 7.84 |
| Short Interest | — | 52W High | 11.68 | 52W Low | 3.96 |
| Beta | 1.78 | Avg Volume | 33.29K | Volume | 16.64K |
| Target Price | $15.00 | Recom | None | Prev Close | $4.11 |
| Price | $4.28 | Change | 4.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$4.28
Latest analyst target
3. DCF / Fair value
$-3.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.28
Low
$15.00
High
$15.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-01-22 | init | Noble Capital Markets | — → Outperform | $13 |
| 2022-07-26 | main | Small Cap Consumer Research | — → Buy | $21 |
- Fentanyl patch, sports tape head to Costa Rica in Nutriband deal - Stock Titan ue, 17 Feb 2026 12
- Nutriband (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products - The Globe and Mail ue, 17 Feb 2026 20
- Nutriband (NTRB) Secures Exclusive Distribution Deal in Costa Ri - GuruFocus ue, 17 Feb 2026 13
- Understanding Momentum Shifts in (NTRB) - Stock Traders Daily Mon, 09 Feb 2026 05
- The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable - Yahoo Finance hu, 29 Jan 2026 08
- How sustainable is NTRB stock dividend payout - 2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - mfd.ru Sat, 14 Feb 2026 20
- Nutriband (NASDAQ:NTRB) shareholders are up 27% this past week, but still in the red over the last five years - simplywall.st ue, 30 Dec 2025 08
- Nutriband stock jumps after FDA meeting for abuse-deterrent fentanyl patch - Investing.com ue, 28 Oct 2025 07
- What's Going On With Nutriband Stock Monday? - Nutriband (NASDAQ:NTRB) - Benzinga Mon, 29 Dec 2025 08
- Nutriband Stock Jumps 17% After Agreement To Sell 90% Of Pocono Pharma For $5 Mln - Nasdaq Mon, 29 Dec 2025 08
- NutriBand Inc. SEC 10-Q Report - TradingView hu, 11 Dec 2025 08
- Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval - GlobeNewswire Wed, 02 Jul 2025 07
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points - Stock Titan Fri, 30 Jan 2026 08
- Nutriband (NASDAQ: NTRB) Highlights Board Appointments, AVERSA Fentanyl Milestones - The Globe and Mail Mon, 02 Feb 2026 08
- Inside the Push to Separate Illicit Fentanyl From Pain Treatment - Stock Titan hu, 18 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.21M | -4.57M | -3.82M | -3.61M |
| TotalUnusualItems | -3.96M | -554.42K | -327.33K | -2.13M |
| TotalUnusualItemsExcludingGoodwill | -3.96M | -554.42K | -327.33K | -2.13M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.48M | -5.49M | -4.48M | -6.18M |
| ReconciledDepreciation | 285.05K | 287.72K | 330.14K | 318.26K |
| ReconciledCostOfRevenue | 1.40M | 1.22M | 1.33M | 917.84K |
| EBITDA | -10.18M | -5.12M | -4.15M | -5.74M |
| EBIT | -10.46M | -5.41M | -4.48M | -6.06M |
| NetInterestIncome | 170.26K | -58.97K | -8.29K | -118.42K |
| InterestExpense | 21.41K | 75.81K | 8.29K | 118.42K |
| InterestIncome | 191.67K | 16.85K | 0.00 | |
| NormalizedIncome | -6.52M | -4.93M | -4.16M | -4.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.48M | -5.49M | -4.48M | -6.18M |
| TotalExpenses | 8.83M | 6.96M | 6.23M | 5.35M |
| TotalOperatingIncomeAsReported | -10.28M | -4.87M | -4.48M | -6.11M |
| DilutedAverageShares | 10.61M | 7.95M | 8.46M | 7.93M |
| BasicAverageShares | 10.61M | 7.95M | 8.46M | 7.93M |
| DilutedEPS | -0.99 | -0.69 | -0.53 | -0.80 |
| BasicEPS | -0.99 | -0.69 | -0.53 | -0.80 |
| DilutedNIAvailtoComStockholders | -10.48M | -5.49M | -4.48M | -6.37M |
| NetIncomeCommonStockholders | -10.48M | -5.49M | -4.48M | -6.37M |
| OtherunderPreferredStockDividend | 0.00 | 196.59K | ||
| NetIncome | -10.48M | -5.49M | -4.48M | -6.18M |
| NetIncomeIncludingNoncontrollingInterests | -10.48M | -5.49M | -4.48M | -6.18M |
| NetIncomeContinuousOperations | -10.48M | -5.49M | -4.48M | -6.18M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -10.48M | -5.49M | -4.48M | -6.18M |
| OtherIncomeExpense | -3.96M | -554.42K | -327.33K | -2.13M |
| SpecialIncomeCharges | -3.96M | -554.42K | -327.33K | -2.13M |
| OtherSpecialCharges | 368.04K | 554.42K | -53.03K | |
| ImpairmentOfCapitalAssets | 3.60M | 0.00 | 327.33K | 2.18M |
| NetNonOperatingInterestIncomeExpense | 170.26K | -58.97K | -8.29K | -118.42K |
| InterestExpenseNonOperating | 21.41K | 75.81K | 8.29K | 118.42K |
| InterestIncomeNonOperating | 191.67K | 16.85K | 0.00 | |
| OperatingIncome | -6.69M | -4.87M | -4.15M | -3.93M |
| OperatingExpense | 7.43M | 5.73M | 4.90M | 4.43M |
| ResearchAndDevelopment | 3.12M | 1.96M | 982.23K | 411.38K |
| SellingGeneralAndAdministration | 4.31M | 3.77M | 3.92M | 4.02M |
| GeneralAndAdministrativeExpense | 4.02M | |||
| OtherGandA | 4.02M | |||
| GrossProfit | 743.32K | 862.11K | 750.41K | 504.31K |
| CostOfRevenue | 1.40M | 1.22M | 1.33M | 917.84K |
| TotalRevenue | 2.14M | 2.09M | 2.08M | 1.42M |
| OperatingRevenue | 2.14M | 2.09M | 2.08M | 1.42M |
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 32.40K | 10.00K | 10.00K | 32.81K |
| OrdinarySharesNumber | 11.07M | 8.86M | 7.83M | 9.15M |
| ShareIssued | 11.11M | 8.87M | 7.84M | 9.18M |
| TotalDebt | 186.35K | 241.28K | 185.81K | 134.57K |
| TangibleBookValue | 4.45M | 749.24K | 2.77M | 5.58M |
| InvestedCapital | 6.62M | 6.65M | 8.69M | 11.97M |
| WorkingCapital | 3.81M | 22.77K | 1.95M | 4.69M |
| NetTangibleAssets | 4.45M | 749.24K | 2.77M | 5.58M |
| CapitalLeaseObligations | 0.00 | 34.28K | 65.57K | 19.33K |
| CommonStockEquity | 6.43M | 6.44M | 8.57M | 11.86M |
| TotalCapitalization | 6.49M | 6.52M | 8.67M | 11.96M |
| TotalEquityGrossMinorityInterest | 6.43M | 6.44M | 8.57M | 11.86M |
| StockholdersEquity | 6.43M | 6.44M | 8.57M | 11.86M |
| GainsLossesNotAffectingRetainedEarnings | -304.00 | -304.00 | -304.00 | -304.00 |
| OtherEquityAdjustments | -304.00 | -304.00 | -304.00 | -304.00 |
| TreasuryStock | 148.55K | 32.64K | 32.64K | 104.47K |
| RetainedEarnings | -38.46M | -27.98M | -22.49M | -18.01M |
| AdditionalPaidInCapital | 45.03M | 34.44M | 31.09M | 29.97M |
| CapitalStock | 11.07K | 8.86K | 7.83K | 9.15K |
| CommonStock | 11.07K | 8.86K | 7.83K | 9.15K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.04M | 1.08M | 883.39K | 880.38K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 58.20K | 79.83K | 134.77K | 101.12K |
| LongTermDebtAndCapitalLeaseObligation | 58.20K | 79.83K | 134.77K | 101.12K |
| LongTermCapitalLeaseObligation | 0.00 | 34.28K | 0.00 | |
| LongTermDebt | 58.20K | 79.83K | 100.50K | 101.12K |
| CurrentLiabilities | 982.85K | 999.09K | 748.61K | 779.26K |
| CurrentDeferredLiabilities | 155.88K | 157.50K | 162.90K | 106.27K |
| CurrentDeferredRevenue | 155.88K | 157.50K | 162.90K | 106.27K |
| CurrentDebtAndCapitalLeaseObligation | 128.14K | 161.46K | 51.03K | 33.45K |
| CurrentCapitalLeaseObligation | 0.00 | 34.28K | 31.29K | 19.33K |
| CurrentDebt | 128.14K | 127.18K | 19.74K | 14.12K |
| OtherCurrentBorrowings | 128.14K | 127.18K | 19.74K | 14.12K |
| CurrentNotesPayable | 0.00 | 0.00 | 0.00 | |
| PayablesAndAccruedExpenses | 698.82K | 680.13K | 534.68K | 639.54K |
| TotalAssets | 7.47M | 7.52M | 9.46M | 12.74M |
| TotalNonCurrentAssets | 2.68M | 6.50M | 6.76M | 7.27M |
| GoodwillAndOtherIntangibleAssets | 1.98M | 5.69M | 5.80M | 6.28M |
| OtherIntangibleAssets | 261.39K | 667.28K | 780.43K | 926.91K |
| Goodwill | 1.72M | 5.02M | 5.02M | 5.35M |
| NetPPE | 695.06K | 806.30K | 960.49K | 998.34K |
| AccumulatedDepreciation | -853.60K | -681.69K | -507.12K | -323.46K |
| GrossPPE | 1.55M | 1.49M | 1.47M | 1.32M |
| OtherProperties | 144.59K | 175.96K | 207.34K | 163.63K |
| MachineryFurnitureEquipment | 1.40M | 1.31M | 1.26M | 1.16M |
| CurrentAssets | 4.79M | 1.02M | 2.69M | 5.47M |
| PrepaidAssets | 196.66K | 211.67K | 365.93K | 370.47K |
| Inventory | 212.04K | 168.60K | 229.34K | 131.65K |
| FinishedGoods | 16.61K | 8.71K | ||
| WorkInProcess | 46.26K | 7.47K | ||
| RawMaterials | 149.18K | 152.43K | ||
| Receivables | 73.85K | 148.65K | 113.05K | 71.38K |
| AccountsReceivable | 73.85K | 148.65K | 113.05K | 71.38K |
| CashCashEquivalentsAndShortTermInvestments | 4.31M | 492.94K | 1.99M | 4.89M |
| CashAndCashEquivalents | 4.31M | 492.94K | 1.99M | 4.89M |
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.72M | -3.58M | -3.07M | -2.89M |
| RepurchaseOfCapitalStock | -148.55K | 0.00 | -119.01K | -104.47K |
| RepaymentOfDebt | -20.66K | -19.76K | -17.80K | -1.63M |
| IssuanceOfDebt | 300.00K | 2.11M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 8.41M | 0.00 | 0.00 | 6.42M |
| CapitalExpenditure | -92.04K | -51.76K | -79.30K | -81.59K |
| InterestPaidSupplementalData | 5.63K | 7.35K | 4.27K | 18.60K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 4.31M | 492.94K | 1.99M | 4.89M |
| BeginningCashPosition | 492.94K | 1.99M | 4.89M | 151.99K |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | ||
| ChangesInCash | 3.82M | -1.49M | -2.91M | 4.74M |
| FinancingCashFlow | 8.54M | 2.09M | 160.07K | 7.63M |
| CashFlowFromContinuingFinancingActivities | 8.54M | 2.09M | 160.07K | 7.63M |
| ProceedsFromStockOptionExercised | 0.00 | 296.88K | 2.94M | |
| NetCommonStockIssuance | 8.26M | 0.00 | -119.01K | 6.31M |
| CommonStockPayments | -148.55K | 0.00 | -119.01K | -104.47K |
| CommonStockIssuance | 8.41M | 0.00 | 0.00 | 6.42M |
| NetIssuancePaymentsOfDebt | 279.34K | 2.09M | -17.80K | -1.63M |
| NetLongTermDebtIssuance | 279.34K | 2.09M | -17.80K | -1.63M |
| LongTermDebtPayments | -20.66K | -19.76K | -17.80K | -1.63M |
| LongTermDebtIssuance | 300.00K | 2.11M | 0.00 | 0.00 |
| InvestingCashFlow | -92.04K | -51.76K | -79.30K | -81.59K |
| CashFlowFromContinuingInvestingActivities | -92.04K | -51.76K | -79.30K | -81.59K |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -92.04K | -51.76K | -79.30K | -81.59K |
| PurchaseOfPPE | -92.04K | -51.76K | -79.30K | -81.59K |
| OperatingCashFlow | -4.63M | -3.53M | -2.99M | -2.81M |
| CashFlowFromContinuingOperatingActivities | -4.63M | -3.53M | -2.99M | -2.81M |
| ChangeInWorkingCapital | 34.09K | 223.22K | -219.32K | -541.38K |
| ChangeInOtherWorkingCapital | -1.62K | -5.40K | 56.64K | 19.42K |
| ChangeInOtherCurrentLiabilities | -34.28K | -31.29K | -36.29K | -9.23K |
| ChangeInPayablesAndAccruedExpense | 23.61K | 198.89K | -104.86K | -145.26K |
| ChangeInPrepaidAssets | 15.01K | 154.26K | 4.55K | -370.47K |
| ChangeInInventory | -43.44K | 60.73K | -97.69K | -78.80K |
| ChangeInReceivables | 74.80K | -153.97K | -41.66K | 42.97K |
| ChangesInAccountReceivables | 74.80K | -153.97K | -41.66K | 42.97K |
| OtherNonCashItems | 31.37K | 31.38K | 151.97K | 564.38K |
| StockBasedCompensation | 1.54M | 742.70K | 732.13K | 897.83K |
| ProvisionandWriteOffofAssets | 0.00 | 118.36K | 0.00 | |
| AssetImpairmentCharge | 3.60M | 0.00 | 327.33K | 2.18M |
| DepreciationAmortizationDepletion | 285.05K | 287.72K | 330.14K | 318.26K |
| DepreciationAndAmortization | 285.05K | 287.72K | 330.14K | 318.26K |
| AmortizationCashFlow | 113.15K | 113.15K | 146.48K | |
| AmortizationOfIntangibles | 113.15K | 113.15K | 146.48K | |
| Depreciation | 171.90K | 174.57K | 183.66K | 318.26K |
| OperatingGainsLosses | 368.04K | 554.42K | 174.03K | -53.03K |
| GainLossOnInvestmentSecurities | 174.03K | |||
| NetIncomeFromContinuingOperations | -10.48M | -5.49M | -4.48M | -6.18M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NTRB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|